Bortezomib in Kidney Transplantation

Abstract EN

Although current therapies for pretransplant desensitization and treatment of antibody-mediated rejection (AMR) have had some success, they do not specifically deplete plasma cells that produce antihuman leukocyte antigen (HLA) antibodies.

Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma (a plasma cell neoplasm), induces plasma cell apoptosis.

In this paper we review the current body of literature regarding the use of this biological agent in the field of transplantation.

Although limited experience with bortezomib may seem to show promise in the realm of transplant recipients desensitization and treatment of AMR, there is also experience that may suggest otherwise.

Bortezomib's role in desensitization protocols and treatment of AMR will be defined better as more clinical data and trials become available.